36 of 53 severe COVID-19 cases improved with remdesivir

Gilead Sciences announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVID-19 who were treated with antiviral drug remdesivir on an individual compassionate use basis.

The research, published Friday in The New England Journal of Medicine, showed that clinical improvement was observed in 36 of 53 patients (68%).

Measurement of its efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy, the research added.